Overlevelsen ved 1, 2 og 3 år var henholdsvis 56, 3%, 34, 7% og 20, 2% for Caelyx sammenlignet med henholdsvis 54, 0%, 23, 6% og 13, 2% for topetecan.
The survival rates at 1, 2 and 3 years were 56.3%, 34.7% and 20.2% respectively on Caelyx, compared to 54.0%, 23.6% and 13.2% on topotecan.